Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02170 BASECARE-B > Key Indicators
02170 BASECARE-B
3.450
-0.050-1.43%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Per Share IndicaTor
Operating Cash Flow Per Share
-26.08% -0.3918 -131.65% -0.8847 -- -0.3107 -- -0.3819
Cash Flow Per Share
-113.68% -0.8991 471.24% 5.9972 -- 6.5727 -- 1.0498
Operating Income Per Share
33.00% 0.2931 -0.43% 0.4798 -- 0.2204 -- 0.4819
Net Asset Per Share
-8.88% 7.2427 358.96% 7.6708 -- 7.9488 -- 1.6713
Basic Earning Per Share
51.35% -0.1169 89.91% -0.6115 -- -0.2404 -- -6.0596
Diluted  Earning Per Share
51.35% -0.1169 89.91% -0.6115 -- -0.2404 -- -6.0596
Profitability
Gross Profit Ratio
-0.22% 44.070% 39.51% 47.668% 24.57% 44.167% -27.52% 34.169%
Operating Profit Ratio
36.95% -46.090% -75.99% -116.018% -141.27% -73.105% -320.48% -65.921%
Net Profit Ratio
63.34% -30.761% 87.59% -134.277% 96.66% -83.914% -12.88% -1082.443%
Earning Before Tax Ratio
37.31% -46.722% 89.22% -117.192% 97.05% -74.523% -14.07% -1086.831%
ROE
69.74% -1.220% -- -14.446% -- -4.033% -- --
ROA
69.73% -1.154% 96.23% -13.418% 99.23% -3.813% -1.61% -356.314%
Yield Quality
Operating Cash To Total Revenue
5.20% -133.648% -132.64% -184.393% -64.71% -140.979% -15.71% -79.261%
Capital Structure
Debt Assets Ratio
90.37% 5.340% -75.79% 4.767% -99.75% 2.805% -97.29% 19.687%
Equity Multipler
3.49% 1.0648 -15.69% 1.0498 -- 1.0289 -- 1.2451
Debt Equity Ratio
95.47% 5.641% -79.58% 5.006% -- 2.886% -- 24.513%
Current Assets To tatal Assets
-5.02% 92.490% 6.70% 94.547% 21.43% 97.380% 16.50% 88.608%
Non Current Assets To Total Assets
186.68% 7.510% -52.14% 5.453% -86.77% 2.620% -52.42% 11.392%
Current Liabilities To tatal Liabilities
-47.36% 49.920% -28.92% 70.277% 2,910.55% 94.832% 1,979.33% 98.868%
Non Current Liabilities To Total Liabilities
869.13% 50.080% 2,524.58% 29.723% -94.66% 5.168% -98.81% 1.132%
Solvency
Current Ratio
-5.22% 34.6976 519.94% 28.2221 1,505.17% 36.6087 106.59% 4.5524
Quick Ratio
-7.57% 33.6148 520.47% 27.67 1,630.85% 36.3688 125.39% 4.4595
Operating Profit To Current Liabilities
11.26% -0.6572 -163.12% -2.0634 -360.26% -0.7406 -368.55% -0.7842
Operrating Cash Flow To Current Liabilities
-33.43% -1.9058 -247.80% -3.2794 -214.21% -1.4283 -28.93% -0.9429
Share Equity Without Minority Interest To Total Liabilities
-49.24% 17.5878 389.82% 19.9824 3,915.63% 34.6508 576.68% 4.0795
Operating Cash Flow To Total Liabilities
29.76% -0.9513 -147.22% -2.3047 -9,359.40% -1.3545 -2,581.00% -0.9322
Operating Profit To Total Liabilities
53.29% -0.3281 -87.03% -1.4501 -13,756.28% -0.7024 -9,642.59% -0.7753
Operating Capacity
Inventory Turnover(T)
-71.42% 0.8826 -53.73% 2.8459 69.87% 3.0885 108.16% 6.1509
Current Assets Turnover(T)
-16.01% 0.0398 -72.38% 0.1071 -81.21% 0.0473 -21.36% 0.3877
Fixed Assets Turnover(T)
-67.16% 0.8457 -13.45% 3.593 56.87% 2.5753 79.55% 4.1512
Total Assets Turnover(T)
-18.17% 0.0372 -69.58% 0.1002 -76.95% 0.0454 -10.33% 0.3295
Growth Ability
Operating Revenue GR 3Y
-- 162.916% -- 252.631% -- -- -- --
Gross Income GR 3Y
-- 132.446% -- 573.625% -- -- -- --
Operating Profit GR 3Y
-- -824.553% -- -157.465% -- -- -- --
EBT GR 3Y
-- 85.269% -- 14.169% -- -- -- --
Net Profit GR 3Y
-- 90.338% -- 2.090% -- -- -- --
Net Profit Attributable To The Parent Company GR 3Y
-- 90.200% -- 0.601% -- -- -- --
Total Assets GR 3Y
-- -- -- 1198.714% -- -- -- --
Share Equity Without Minority Interest GR 3Y
-- -- -- 550.071% -- -- -- --
Equity GR 3Y
-- -- -- 545.172% -- -- -- --
Total Liabilities GR 3Y
-- -- -- -83.614% -- -- -- --
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Bei Kang mission Let more families have healthy babies We focus on the application and research of genetic science and technology in the field of fertility to help infertile patients "give birth", so that patients carrying family genetic disease genes "eugenics" to contribute to national and national eugenics. Bei Kang Vision Become the world's leading genetic technology company. Provide comprehensive third-generation test tube solutions for clinical institutions Suzhou Beikang Medical Co., Ltd., as a leader in the NGS market segment-reproductive field, is committed to the R & D and clinical application of high-throughput sequencing technology in the field of reproductive health. It is a "unicorn" breeding enterprise in Suzhou, with a production center of 1364 on the B3 floor and a research center of 6271 on the A3 floor. Since its inception, the company has been adhering to the concept of "making compliance products" and adhering to the road of compliance research and development, registration and certification. In 2015, we declared that the National Standard Management Center defined the PGT-A kit as "three types of medical devices" for supervision; in 2016, the kit successfully won the "National Special approval for innovative Medical Devices" to enter clinical trials; in 2017, we participated in the formulation of PGT-A quality control evaluation guidelines, filling in the gap in the technical standards for quality control of the third generation of test-tube babies in China. In the same year, we built a standard clean production workshop in line with laws and regulations and GMP requirements and passed the provincial medical inspection and inspection. In 2019, we completed the third-generation test-tube PGT-A clinical trial big data verification; on February 21, 2020, the product was approved by the State Drug Administration to be listed on the market, marking the third-generation test-tube baby technology in China has entered a licensed era of medical device supervision and filled the domestic gap. In the future, we will continue to focus on the application and research of genetic technology in the field of fertility to help infertile patients "give birth" and "eugenics" for patients with family genetic diseases. We hope to change our lives through technological innovation, so that more families can have healthy babies, contribute to national and national eugenics, and make continuous progress towards an international brand in the field of reproduction. Bei Kang culture The values of the Baikang people Peikang people adhere to the concept of "strive for every minute and second, Bei Kang speed; everything exacting perfection, Bei Kang standard; everything go all out, Bei Kang spirit" to do everything well. Bay and Base homonyms represent the smallest unit of human genetic information; Kang and Care homonyms represent care and care for human health. Bei Kang course Ten years of gratitude, wind and rain Ten years of wind and rain, spring and autumn; ten years of towering, towering; ten years of gratitude, colleagues have you. Looking back on this decade, it is full of hardship and sweat, as well as passion and hope. We are grateful to Baikang people for polishing our products and providing good service. We are grateful to those who have given us help and support. It is your encouragement that keeps us moving forward.
CEO: Bo Liang
Market: Hong Kong motherboard
Listing Date: 02/08/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist